Explore more publications!
North Dakota Technology Review
Got News to Share?

North Dakota Technology Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Dakota Technology Review.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on December 23, 2025

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
December 23, 2025

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Indeterminate GlobeNewswire
Virtune lanciert Virtune Staked Ethereum ETP und Virtune Chainlink ETP an der Deutschen Börse Xetra in Deutschland
December 23, 2025

Virtune lanciert Virtune Staked Ethereum ETP und Virtune Chainlink ETP an der Deutschen Börse Xetra in Deutschland

Indeterminate GlobeNewswire
Virtune lists Virtune Staked Ethereum ETP and Virtune Chainlink ETP on Deutsche Börse Xetra in Germany
December 23, 2025

Virtune lists Virtune Staked Ethereum ETP and Virtune Chainlink ETP on Deutsche Börse Xetra in Germany

Indeterminate GlobeNewswire
CancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025
December 23, 2025

CancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025

Indeterminate GlobeNewswire
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
December 23, 2025

Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland

Indeterminate GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
December 23, 2025

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Indeterminate GlobeNewswire
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique
December 23, 2025

Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique

Indeterminate GlobeNewswire
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
December 23, 2025

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Indeterminate GlobeNewswire
A Decade to the Top of the World: Geekvape Marks Its 10th Anniversary by Reaching the Summit of Everest
December 23, 2025

A Decade to the Top of the World: Geekvape Marks Its 10th Anniversary by Reaching the Summit of Everest

Indeterminate GlobeNewswire
Free Spins No Deposit UK 2026 - Get 25 Free Spins On Registration No Deposit By Cafe Casino
December 23, 2025

Free Spins No Deposit UK 2026 - Get 25 Free Spins On Registration No Deposit By Cafe Casino

Indeterminate GlobeNewswire
Burning Rock Announces Results of 2025 Annual General Meeting
December 23, 2025

Burning Rock Announces Results of 2025 Annual General Meeting

Indeterminate GlobeNewswire
UPDATE -- OBOOK Holdings Inc. (OWLS) issues Year-End CEO Letter to Shareholders
December 23, 2025

UPDATE -- OBOOK Holdings Inc. (OWLS) issues Year-End CEO Letter to Shareholders

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions